LTL Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
LTL Pharma - overview
Established
2016
Location
Tokyo, Tokyo, Japan
Primary Industry
Pharmaceuticals
About
Founded in 2026 and located in Tokyo, Japan, LTL Pharma Co. , Ltd. , d. b.
a LTL Pharma, focusing on the production and distribution of long-life pharmaceuticals. The company focuses on the administration and consistent provision of Long-term Listed (LTL) medications, which are also referred to as off-patent or legacy brands. In February 2026, Oji Holdings and Unison Capital fully acquired LTL Pharma Co. , Ltd.
from Japan Established Medicines Corporation. LTL Pharma Co. , Ltd. specializes in the production and distribution of long-life pharmaceuticals, including a range of antibiotics and essential medical products.
These medications are integral in various therapeutic areas and continue to be prescribed for their efficacy and safety. The company caters primarily to healthcare professionals, hospitals, and clinics, ensuring that its products are available in both domestic and international markets, thus meeting diverse patient needs. In the most recent fiscal year of 2022, LTL Pharma generated a revenue of USD 154. 15 mn through direct sales of its pharmaceuticals to healthcare providers, including hospitals and clinics.
The company primarily engages in B2B transactions, partnering with healthcare facilities to supply critical long-life medications, particularly key antibiotics that play a vital role in treating infections. The company plans to use the February 2026 funding to acquire pharmaceutical expertise and establishing drug platform for biomass-based pharmaceutical operations, and continued expansion of LTL as a long-listed drug platform.
Current Investors
Japan Established Medicines Corporation
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.ltl-pharma.com
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
LTL Pharma - financials
| Fiscal Year Ended | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue (USD) | 10,641,872,000 | 12,007,483,000 | - | - | - |
| % Revenue Growth (YoY) | - | 12.8% | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | 5,239,395,000 | 2,030,582,000 | - | - | - |
| Operating Margin | 49.2% | 16.9% | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | 3,082,620,000 | 2,215,502,000 | - | - | - |
| % Net Margin | 29.0% | 18.5% | - | - | - |
LTL Pharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | LTL Pharma | - | ||||||||
| Add-on | Completed | LTL Pharma | - |
Displaying 1 - 2 of 2
LTL Pharma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.